tert-butyl (2-oxo-1,2,3,4-tetrahydro-1,5-naphthyridin-3-yl)carbamate | 600157-68-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: tert-butyl (2-oxo-1,2,3,4-tetrahydro-1,5-naphthyridin-3-yl)carbamate
• 英文别名: tert-butyl (2-oxo-1,2,3,4-tetrahydro-1,5-naphthyridine-3-yl)carbamate；tert-butyl N-(2-oxo-3,4-dihydro-1H-1,5-naphthyridin-3-yl)carbamate
• CAS: 600157-68-4
• 化学式: C₁₃H₁₇N₃O₃
• 分子量: 263.296
• InChiKey: SLKKJBHQVMRDBX-UHFFFAOYSA-N

物化性质

• 沸点：
  473.3±45.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  80.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (2-oxo-1,2,3,4-tetrahydro-1,5-naphthyridin-3-yl)carbamate 在 盐酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 0.5h， 以100%的产率得到3-amino-3,4-dihydro-1,5-naphthyridin-2(1H)-one dihydrochloride
  参考文献：
  名称：

  [EN] HETEROCYCLIC AMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE
  [FR] DERIVES D'AMIDES HETEROCYCLIQUES COMME INHIBITEURS DE LA GLYCOGENE PHOSPHORYLASE

  摘要：

  式（1）的杂环酰胺，其中：X为N或CH；R4和R5一起是-S-C（R6）=C（R7）-或-C（R7）=C（R6）-S-；R6和R7可独立地选择自氢、卤素和C1-4烷基；A为苯基或杂芳基；n为0、1或2；R1可从卤素、硝基、氰基、羟基、羧基中选择；R2为氢、羟基或羧基；R3可从氢、羟基、芳基、杂环烷基和C1-4烷基中选择（可选地由1或2个R8基取代）；R8可从羟基、-COCOOR9、-C（O）N（R9）（R10）、-NHC（O）R9、（R9）（R10）N-和-COOR9中选择；R9和R10可从氢、羟基、C1-4烷基（可选地由1或2个R13取代）中选择；R13可从羟基、卤素、三卤甲基和C1-4烷氧基中选择；或其药学上可接受的盐或前药；具有糖原磷酸化酶抑制活性，因此在治疗与糖原磷酸化酶活性增加相关的疾病状态中具有价值。描述了制备所述杂环酰胺衍生物和含有它们的药物组合物的方法。

  公开号：

  WO2003074532A1
• 作为产物：
  描述：

  Methyl 3-(3-aminopyridin-2-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成 tert-butyl (2-oxo-1,2,3,4-tetrahydro-1,5-naphthyridin-3-yl)carbamate
  参考文献：
  名称：

  [EN] HETEROCYCLIC AMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE
  [FR] DERIVES D'AMIDES HETEROCYCLIQUES COMME INHIBITEURS DE LA GLYCOGENE PHOSPHORYLASE

  摘要：

  式（1）的杂环酰胺，其中：X为N或CH；R4和R5一起是-S-C（R6）=C（R7）-或-C（R7）=C（R6）-S-；R6和R7可独立地选择自氢、卤素和C1-4烷基；A为苯基或杂芳基；n为0、1或2；R1可从卤素、硝基、氰基、羟基、羧基中选择；R2为氢、羟基或羧基；R3可从氢、羟基、芳基、杂环烷基和C1-4烷基中选择（可选地由1或2个R8基取代）；R8可从羟基、-COCOOR9、-C（O）N（R9）（R10）、-NHC（O）R9、（R9）（R10）N-和-COOR9中选择；R9和R10可从氢、羟基、C1-4烷基（可选地由1或2个R13取代）中选择；R13可从羟基、卤素、三卤甲基和C1-4烷氧基中选择；或其药学上可接受的盐或前药；具有糖原磷酸化酶抑制活性，因此在治疗与糖原磷酸化酶活性增加相关的疾病状态中具有价值。描述了制备所述杂环酰胺衍生物和含有它们的药物组合物的方法。

  公开号：

  WO2003074532A1

文献信息

• [EN] HETEROCYCLIC AMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE<br/>[FR] DERIVES D'AMIDES HETEROCYCLIQUES COMME INHIBITEURS DE LA GLYCOGENE PHOSPHORYLASE
  申请人：ASTRAZENECA AB

  公开号：WO2003074532A1

  公开（公告）日：2003-09-12

  Heterocyclic amides of formula (1) wherein: X is N or CH; R4 and R5 together are either -S-C(R6)=C(R7)- or -C(R7)=C(R6)-S-; R6 and R7 are independently selected from, for example hydrogen, halo and C1-4alkyl; A is phenylene or heteroarylene; n is 0, 1 or 2; R1 is selected from for example halo, nitro, cyano, hydroxy, carboxy; R2 is hydrogen, hydroxy or carboxy; R3 is selected from for example hydrogen, hydroxy, aryl, heterocyclyl and C1-4alkyl (optionally substituted by 1 or 2 R8 groups); R8 is selected from for example hydroxy, -COCOOR9, -C(O)N(R9)(R10), -NHC(O)R9, (R9)(R10)N- and -COOR9; R9 and R10 are selected from for example hydrogen, hydroxy, C1-4alkyl (optionally substituted by 1 or 2 R13); R13 is selected from hydroxy, halo, trihalomethyl and C1-4alkoxy; or a pharmaceutically acceptable salt or pro-drug thereof; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.

  式（1）的杂环酰胺，其中：X为N或CH；R4和R5一起是-S-C（R6）=C（R7）-或-C（R7）=C（R6）-S-；R6和R7可独立地选择自氢、卤素和C1-4烷基；A为苯基或杂芳基；n为0、1或2；R1可从卤素、硝基、氰基、羟基、羧基中选择；R2为氢、羟基或羧基；R3可从氢、羟基、芳基、杂环烷基和C1-4烷基中选择（可选地由1或2个R8基取代）；R8可从羟基、-COCOOR9、-C（O）N（R9）（R10）、-NHC（O）R9、（R9）（R10）N-和-COOR9中选择；R9和R10可从氢、羟基、C1-4烷基（可选地由1或2个R13取代）中选择；R13可从羟基、卤素、三卤甲基和C1-4烷氧基中选择；或其药学上可接受的盐或前药；具有糖原磷酸化酶抑制活性，因此在治疗与糖原磷酸化酶活性增加相关的疾病状态中具有价值。描述了制备所述杂环酰胺衍生物和含有它们的药物组合物的方法。
• [EN] TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES<br/>[FR] TETRAHYDROQUINOLONES ET AZA-ANALOGUES ASSOCIES UTILISES EN TANT QU'INHIBITEURS DE LA DPP-IV DANS LE TRAITEMENT DU DIABETE
  申请人：ASTRAZENECA AB

  公开号：WO2005123685A1

  公开（公告）日：2005-12-29

  Compound of formula (I) or a pharmaceutically-acceptable salt thereof, formula (I) wherein Ar is optionally substituted phenyl; R1 is selected from: formula a) or b) (wherein is a single or double bond); R5, R6, R7 and R8 are for example hydrogen or alkyl; R4 is selected from hydrogen, (3-4C)cycloalkyl and optionally substituted (1-4C)alkyl; R10 is for example selected from hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl(1-4C)alkyl, hydroxy(1-4C)alkyl, (1-4C)alkoxy, aryl(1-4C)alkyl; Y is carbon and Ring A is optionally substituted phenylene; or each Y may independently be carbon or nitrogen and Ring A is optionally substituted 5- or 6-membered, heteroarylene ring; R11 is selected from hydrogen and optionally substituted phenyl; p is independently at each occurrence 0, 1 or 2; are described. Processes for making such compounds and their use as DPP-IV inhibitors in the treatment of diabetes are also described.

  化合物的化学式（I）或其药用可接受的盐，其中化学式（I）中Ar是可选择的取代苯基；R1选自：化学式a）或b）（其中是单键或双键）；R5、R6、R7和R8例如是氢或烷基；R4选自氢、（3-4C）环烷基和可选择的取代（1-4C）烷基；R10例如选自氢、（1-4C）烷基、（3-6C）环烷基（1-4C）烷基、羟基（1-4C）烷基、（1-4C）烷氧基、芳基（1-4C）烷基；Y是碳，环A是可选择的取代苯基；或每个Y可以独立地是碳或氮，环A是可选择的取代的5-或6-成员的杂芳烃环；R11选自氢和可选择的取代苯基；p在每次出现时独立地为0、1或2；描述了制备这类化合物的过程以及它们作为DPP-IV抑制剂在糖尿病治疗中的用途。
• [EN] 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER<br/>[FR] DÉRIVÉS DE 1,2,3,4-TÉTRAHYDROQUINOLINE SERVANT D'INHIBITEURS DE L'ACTIVATION DE YAP/TAZ-TEAD POUR LE TRAITEMENT DU CANCER
  申请人：UNIV LEUVEN KATH

  公开号：WO2022072741A1

  公开（公告）日：2022-04-07

  The present invention relates to novel compounds of formula (la), to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/ TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/ TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present invention also relates to processes for the preparation of said compounds.

  本发明涉及化合物（la）的新颖化合物，以及将该化合物用作药物，更具体地用于预防或治疗由YAP / TAZ-TEAD转录活性介导的疾病，更具体地用于预防或治疗癌症或纤维化。本发明还涉及一种预防或治疗该疾病的方法，包括使用新颖化合物。本发明还涉及新颖化合物的药物组成物或组合制剂，以及将该组成物或制剂用作药物，更具体地用于预防或治疗由YAP / TAZ-TEAD转录活性介导的疾病，更具体地用于预防或治疗癌症或纤维化。本发明还涉及制备该化合物的方法。
• HETEROCYCLIC AMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE
  申请人：Birch Martin Alan

  公开号：US20070043069A1

  公开（公告）日：2007-02-22

  Heterocyclic amides of formula (1) wherein: X is N or CH; R 4 and R 5 together are either —S—C(R 6 )═C(R 7 )— or —C(R 7 )═C(R 6 )—S—; R 6 and R 7 are independently selected from, for example hydrogen, halo and C 1-4 alkyl; A is phenylene or heteroarylene; n is 0, 1 or 2; R 1 is selected from for example halo, nitro, cyano, hydroxy, carboxy; R 2 is hydrogen, hydroxy or carboxy; R 3 is selected from for example hydrogen, hydroxy, aryl, heterocyclyl and C 1-4 alkyl(optionally substituted by 1 or 2 R 8 groups); R 8 is selected from for example hydroxy, —COCOOR 9 , —C(O)N(R 9 )(R 10 ), —NHC(O)R 9 , (R 9 )(R 10 )N— and —COOR 9 ; R 9 and R 10 are selected from for example hydrogen, hydroxy, C 1-4 alkyl (optionally substituted by 1 or 2 R 13 ); R 13 is selected from hydroxy, halo, trihalomethyl and C 1-4 alkoxy; or a pharmaceutically acceptable salt or pro-drug thereof, possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.

  式（1）的杂环酰胺，其中：X为N或CH；R4和R5组合在一起是—S—C(R6)═C(R7)—或—C(R7)═C(R6)—S—；R6和R7独立选择自例如氢、卤素和C1-4烷基；A为苯撑或杂芳撑；n为0、1或2；R1选择自例如卤素、硝基、氰基、羟基、羧基；R2为氢、羟基或羧基；R3选择自例如氢、羟基、芳基、杂环基和C1-4烷基（可以选择性地被1或2个R8基取代）；R8选择自例如羟基、—COCOOR9、—C(O)N(R9)(R10)、—NHC(O)R9、(R9)(R10)N—和—COOR9；R9和R10选择自例如氢、羟基、C1-4烷基（可以选择性地被1或2个R13取代）；R13选择自羟基、卤素、三卤甲基和C1-4烷氧基；或其药学上可接受的盐或前药具有糖原磷酸化酶抑制活性，因此在治疗与增加的糖原磷酸化酶活性相关的疾病状态方面具有价值。描述了制备该杂环酰胺衍生物的方法和含有它们的药物组合物。
• PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES
  申请人：Krulle Thomas Martin

  公开号：US20090099176A1

  公开（公告）日：2009-04-16

  Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants.

  式(I)所代表的化合物或其药学上可接受的盐，可用于预防或治疗糖尿病、高血糖、高胆固醇血症、高胰岛素血症、高脂血症、高血压、动脉粥样硬化或组织缺血，例如心肌缺血，并作为心脏保护剂。